(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 23.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Foghorn Therapeutics's revenue in 2025 is $23,504,000.On average, 5 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,887,068,442, with the lowest FHTX revenue forecast at $1,429,766,217, and the highest FHTX revenue forecast at $2,787,068,650. On average, 5 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,334,448,701, with the lowest FHTX revenue forecast at $1,615,942,403, and the highest FHTX revenue forecast at $3,344,482,380.
In 2027, FHTX is forecast to generate $2,388,963,764 in revenue, with the lowest revenue forecast at $1,923,077,369 and the highest revenue forecast at $2,787,068,650.